Abstract
1152P - Evaluation of the pharmacokinetic (PK) profile of vismodegib (VISMO) in patients (pts) with multiple basal cell carcinomas (BCCs) across two intermittent treatment regimens in the MIKIE study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have